CCL2 and hepatocellular carcinoma: Along with FoxO1, CCL2 promotes the COX-2/PGE2 pathway in a p38-MAPK-dependent manner, thereby inhibiting the release of pro-inflammatory cytokines by macrophages and HCC progression.